With genome-wide association studies involving more than 200,000 individuals, researchers narrowed in on 58 loci and dozens of genes with ties to a chronic infection marker.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
In Genome Biology this week: parainflammation found in some cancers, recurrent copy number changes affecting metabolic genes in cancer, and more.
In blood samples from infected individuals, a seven-gene signature apparently distinguishes between bacterial and viral culprits, a distinction important to antibiotic use.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The genetic testing firm is developing a plan to drive market adoption of its PerioPredict test for inflammation-related genes.
The FDA considers Interleukin Genetics' PerioPredict test and the DNA-CardioCheck test to be medical devices.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.